Tirzepatide for PCOS UK: Weight Loss, Fertility & Research Evidence

Polycystic ovary syndrome (PCOS) is one of the most common hormonal conditions affecting women of reproductive age in the UK, with prevalence estimates of 8–13% of women. Understanding the metabolic basis of PCOS is essential to appreciating why medications like tirzepatide may be particularly relevant.

The central metabolic problem in PCOS: - The majority of women with PCOS (approximately 70–80%) have insulin resistance — impaired cellular response to insulin, leading to compensatory hyperinsulinaemia - Elevated insulin levels stimulate the ovaries to produce excess androgens (testosterone, androstenedione) — the primary driver of symptoms including irregular periods, hirsutism, acne and ovarian cysts - Excess weight, particularly central/visceral fat, worsens insulin resistance, creating a cycle that perpetuates PCOS symptoms - Conversely, weight loss — even modest amounts of 5–10% — is associated with significant improvements in menstrual regularity, androgen levels and fertility in women with PCOS

Why PCOS makes weight loss difficult: - Insulin resistance impairs the body's ability to use fat as fuel - Elevated androgens may alter appetite regulation - Many women with PCOS report that standard caloric restriction produces less weight loss than expected - This metabolic disadvantage makes pharmacological support for weight loss particularly valuable in PCOS

*This article is for educational purposes only. PCOS management should be discussed with your GP, gynaecologist or endocrinologist.*

The primary clinical evidence for tirzepatide in weight management comes from the SURMOUNT trial programme. Whilst SURMOUNT trials were not designed specifically for PCOS populations, sub-analyses and emerging data provide relevant insights.

SURMOUNT-1 and SURMOUNT-4 overview: - SURMOUNT-1 enrolled adults with BMI ≥30 (or ≥27 with comorbidity) without Type 2 diabetes - Mean weight loss at 72 weeks: 15.7% (5mg), 19.9% (10mg), 20.9% (15mg) from baseline - Women in the SURMOUNT trials who had metabolic syndrome features (high insulin, elevated androgens) showed improvements consistent with the overall population

PCOS-relevant sub-analyses: - A proportion of SURMOUNT-1 participants had pre-existing PCOS diagnoses; sub-group data showed weight loss and metabolic improvements consistent with the overall trial - Improvements in fasting insulin, HOMA-IR (insulin resistance index) and testosterone were observed in women achieving significant weight loss on tirzepatide - The dual GIP/GLP-1 mechanism may have particular relevance for PCOS: GIP receptor activation has effects on adipose tissue metabolism that could complement GLP-1's insulin-sensitising properties

What is still uncertain: - No large-scale PCOS-specific randomised controlled trial for tirzepatide has been published as of early 2026 - Most evidence is extrapolated from broader weight management and metabolic trials - Semaglutide has slightly more direct PCOS-relevant data, including the STEP-PCOS analysis (2024), which found significant improvements in menstrual frequency, androgen levels and quality of life

Beyond weight loss, tirzepatide's direct effects on insulin resistance may be particularly relevant for PCOS.

Mechanism of insulin sensitisation: - GLP-1 receptor agonism promotes glucose-dependent insulin secretion whilst suppressing glucagon, reducing postprandial glucose spikes - GIP receptor activation has direct effects on adipose tissue — potentially improving the quality of fat tissue rather than simply reducing quantity - Reduced visceral fat (which tirzepatide depletes preferentially) directly improves hepatic and peripheral insulin sensitivity

Measured metabolic improvements in trial data: - HOMA-IR reduction: Significant improvements in insulin resistance markers observed at all tirzepatide doses in SURMOUNT trials - Fasting insulin: Reduced meaningfully in participants achieving 10%+ weight loss - HbA1c and fasting glucose: Improvements even in non-diabetic participants with insulin resistance - Triglycerides and HDL cholesterol: Favourable changes observed, relevant because PCOS commonly involves dyslipidaemia

Androgen levels: - Weight loss achieved with tirzepatide is associated with reductions in free androgen index (FAI) and total testosterone - Reductions in androgens correlate with improvements in hirsutism score and menstrual regularity in women with PCOS - These changes are thought to be primarily weight-loss mediated rather than a direct peptide effect on androgen synthesis — but the clinical outcome is the same

SHBG: Sex hormone-binding globulin (SHBG), which is typically low in PCOS, tends to increase with weight loss and insulin resistance improvement — further reducing free androgen levels.

Fertility is a primary concern for many women with PCOS. Understanding how tirzepatide may affect fertility — and the important precautions required — is essential.

Potential positive effects on fertility: - Restoration of regular menstrual cycles is the most reliable predictor of ovulation resumption in PCOS - Studies in PCOS consistently show that 5–10% weight loss can restore ovulation in 30–60% of anovulatory women with PCOS - If tirzepatide-mediated weight loss achieves this threshold, the fertility benefits could be significant - Improved insulin sensitivity may restore normal hypothalamic-pituitary-ovarian signalling

Critical safety warning — contraception requirement: - Tirzepatide is contraindicated in pregnancy — there is no human safety data and animal studies show teratogenicity - Women of childbearing potential must use effective contraception throughout treatment - There is a theoretical interaction between tirzepatide and oral contraceptives — delayed gastric emptying may reduce oral contraceptive absorption; barrier methods or non-oral contraception are preferred during dose titration - Because tirzepatide may restore ovulation in women who previously had irregular cycles, the contraception requirement is especially important — women who believed they were unlikely to conceive may become fertile on treatment

Planning a pregnancy: - Current guidance suggests stopping tirzepatide at least 1 month before planned conception (and ideally longer to allow full drug elimination) - Discuss fertility planning with your prescriber before starting treatment - Referral to a reproductive endocrinologist is appropriate for women with PCOS who are actively trying to conceive

For women with PCOS in the UK, understanding the prescribing landscape and how tirzepatide compares with the established standard of care is important.

Metformin for PCOS — the current standard: - Metformin (an oral biguanide originally developed for T2D) is the most commonly prescribed insulin-sensitising agent for PCOS in the UK - It is licensed for Type 2 diabetes but used off-label for PCOS — GPs can prescribe it on this basis - Evidence: modest improvements in insulin resistance, modest weight loss (typically 2–3%), improvement in menstrual regularity in some patients - Side effects: predominantly gastrointestinal (nausea, diarrhoea) in the first few weeks - Cost: extremely low (NHS generic, pence per day)

Tirzepatide vs metformin for PCOS: - Tirzepatide is not currently licensed for PCOS and is not available on the NHS for this indication - Weight loss with tirzepatide (15–20%) vastly exceeds metformin (2–3%) - Insulin resistance improvements are substantially greater with tirzepatide - For women with significant obesity-related PCOS, tirzepatide may offer benefits that metformin simply cannot match - However, tirzepatide requires injection, specialist oversight, and private funding in the current UK context

NHS access pathways for PCOS patients: - GPs can prescribe metformin immediately for PCOS - GLP-1 agonists (Wegovy, Mounjaro) can be accessed via NHS Tier 3 weight management services if BMI criteria are met — PCOS is a qualifying comorbidity at some ICBs - Private prescribing of tirzepatide specifically for PCOS metabolic management is possible through specialist endocrinology or PCOS clinics

*This article is for educational purposes only. PCOS treatment should be supervised by a qualified clinician. Fertility implications of any treatment should be discussed with a specialist.*